Regeneron said on Friday the U.S. Food and Drug Administration has once again declined to approve its blood cancer therapy, ...

Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug ...

In statements to the USA TODAY Network, both the University of Rochester Medical Center, or URMC, and Regeneron noted they don't receive federal funding connected to the mRNA research cuts announced ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

The Regeneron litigation highlights that donations routed through independent entities are not immune from challenge, especially if the government believes they are effectively covering a patient’s co ...

RBC Capital analyst Brian Abrahams maintained the stock with a Sector Perform and raised the price target from $688 to $695.

Regeneron (REGN) stock in focus as the company surpasses Street's Q2 projections with strong growth in high-dose Eylea, ...

Regeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects separate ...

Q2 2025 Earnings Call Transcript August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...

Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, ...